Back to Search
Start Over
Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks
- Source :
- Vaccines, Volume 9, Issue 10, Vaccines, Vol 9, Iss 1130, p 1130 (2021)
- Publication Year :
- 2021
- Publisher :
- MDPI AG, 2021.
-
Abstract
- It has been demonstrated that patients on hemo- or peritoneal dialysis are particularly susceptible to SARS-CoV-2 infection and impaired seroconversion compared to healthy controls. Follow-up data on vaccination response in dialysis patients is limited but is greatly needed to individualize and guide (booster) vaccination strategies. In this prospective, multicenter study we measured anti-spike S1 and neutralizing antibodies in 124 hemodialysis patients, 41 peritoneal dialysis patients, and 20 age- and sex-matched healthy controls over 12 weeks after homologous BNT162b2 vaccination. Compared to healthy controls, both hemodialysis and peritoneal dialysis patients had lower anti-S1 IgG antibodies (median (IQR) 7.0 (2.8–24.3) and 21.8 (5.8–103.9) versus 134.9 (23.8–283.6), respectively<br />p &lt<br />0.001 and p &lt<br />0.05) and a reduced SARS-CoV-2 spike protein–ACE2 binding inhibition caused by vaccine-induced antibodies (median (IQR) 56% (40–81) and 77% (52–89) versus 96% (90–98), respectively<br />0.01) three weeks after the second vaccination. Twelve weeks after the second vaccination, the spike protein–ACE2 binding inhibition significantly decreased to a median (IQR) of 45% (31–60) in hemodialysis patients and 55% (36–78) in peritoneal dialysis patients, respectively (p &lt<br />0.05). Peritoneal dialysis patients mounted higher antibody levels compared with hemodialysis patients at all time points during the 12-week follow-up. Individual booster vaccinations in high-risk individuals without seroconversion or rapidly waning neutralizing antibody levels are required and further data on the neutralization of emerging variants of concern in these patients are urgently needed.
- Subjects :
- medicine.medical_specialty
COVID-19 vaccination
Coronavirus disease 2019 (COVID-19)
medicine.medical_treatment
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Immunology
Gastroenterology
Article
Peritoneal dialysis
Internal medicine
Drug Discovery
medicine
Pharmacology (medical)
Seroconversion
Neutralizing antibody
Pharmacology
hemodialysis
vaccination strategy
biology
SARS-CoV-2
business.industry
COVID-19
Vaccination
Infectious Diseases
peritoneal dialysis
biology.protein
Medicine
BNT162b2
Hemodialysis
Antibody
business
humoral response
Subjects
Details
- ISSN :
- 2076393X
- Volume :
- 9
- Database :
- OpenAIRE
- Journal :
- Vaccines
- Accession number :
- edsair.doi.dedup.....c5ecc23bbce63e36c011e69966d10a16